Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.

Volltext-Artikel, E-Books und Literaturhinweise aus dem EBSCO Discovery Service

"Artikel & mehr" berücksichtigt nur einen Teil der für die Bibliothek der Frankfurt UAS verfügbaren Datenbanken. Zur Übersicht in DBIS

Ergebnis verändern

einschränken: Volltextzugriff; Academic (peer-reviewed) journals
erweitern: Auch Volltexte der Artikel durchsuchen; Verwandte Themen suchen

Publikationstyp

Thema

erschienen in

Verlag

Geographic terms

Sprache

Datenbank

Erscheinungsjahr

Von:

Bis:

Treffer 1 - 25 von 330, Suchdauer: 4.49s

12 3 4 5 6 7 8 9 10 11 weiter »

1
Effects of volenrelaxin in worsening heart failure with preserved ejection fraction: a phase 2 randomized trial

von Borlaug, Barry A. ; Testani, Jeffrey M. ; Petrie, Mark C. ; et al.

Nature Medicine. 31(11):3853-3861
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

2
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

von Heerspink H. J. L. ; Agarwal R. ; Bakris G. L. ; et al.

Schlagworte: clinical trial; eGFR slope; finerenone; immunoglobulin A nephropathy; non-diabetic chronic kidney disease
- View full text via BASE
Merkliste

3
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

von Packer, M ; Anker, S ; Butler, J ; et al.

In The Lancet Diabetes & Endocrinology January 2022 10(1):35-45
- View full text via DOI
Merkliste

4
Vaccine Immunity Against Pneumococcus in Children With Cochlear Implants.

von Hominal, Audrey ; Gualtieri, Renato ; Lemaitre, Barbara ; et al.

Pediatric Infectious Disease Journal; Feb2026, Vol. 45 Issue 2, p187-193, 7p
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

5
Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

von Plitt, Anna ; Ezekowitz, Michael D. ; De Caterina, Raffaele ; et al.

Schlagworte: 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

6
Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study

von Campos, R. ; Chacón, C. ; Cursack, G. ; et al.

In The Lancet Global Health July 2017 5(7):e665-e672
- View full text via DOI
Merkliste

7
Edoxaban versus Warfarin in Patients with Atrial Fibrillation

von Giugliano, Robert P. ; Ruff, Christian T. ; Braunwald, Eugene ; et al.

Schlagworte: 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

8
Diet and Clinical Outcomes in a Heart Failure Population

von Yusuf, S. ; Joseph, P. ; Leong, D. ; et al.

In JACC: Heart Failure April 2026 14(4)
- View full text via DOI
Merkliste

9
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

von Link, Mark S. ; Giugliano, Robert P. ; Ruff, Christian T. ; et al.

Schlagworte: atrial fibrillation; bleeding; mortality; stroke; thromboembolism; 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

10
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials

von Armstrong, Paul W. ; O'Connor, Christopher M. ; Pieske, Burkert ; et al.

In The Lancet 27 September-3 October 2025 406(10510):1351-1362
- View full text via DOI
Merkliste

11
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial

von Wang, Kaijun ; Li, Haiyan ; Kwong, Winghan J. ; et al.

Schlagworte: anticoagulation; bleeding; quality of life; utility; 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

12
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial

von Cadena, Alberto ; Nunez Villota, Julio ; Echeverria, Luis ; et al.

In The Lancet 27 September-3 October 2025 406(10510):1341-1350
- View full text via DOI
Merkliste

13
Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)

von Rost, Natalia S. ; Giugliano, Robert P. ; Ruff, Christian T. ; et al.

Schlagworte: atrial fibrillation; clinical trial; hemorrhage; risk factors; stroke; 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

14
LIBELULE: A Randomized Phase III Study to Evaluate the Clinical Relevance of Early Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer

von Swalduz, Aurélie ; Schiffler, Camille ; Curcio, Hubert ; et al.

In Journal of Thoracic Oncology April 2025 20(4):437-450
- View full text via DOI
Merkliste

15
Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48

von Giugliano, Robert P. ; Ruff, Christian T. ; Rost, Natalia S. ; et al.

Schlagworte: anticoagulant; atrial fibrillation; cerebral hemorrhage; stroke; 03 Good Health and Well-being; 03 Salud y bienestar
- Volltextverfügbarkeit prüfen (via ReDI)
Merkliste

16
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08–2015 ENERGY): a randomised, open-label, phase 3 study

von LENA, Hervé ; VERGNENEGRE, Alain ; LOCHER, Chrystèle ; et al.

In The Lancet Respiratory Medicine
- View full text via DOI
Merkliste

17
Real-life nationwide characteristics and outcomes of small cell lung cancer over the last 20 years: Impact of immunotherapy on overall survival in a real-life setting

von Falchero, Lionel ; Meyer, Nicolas ; Molinier, Olivier ; et al.

In European Journal of Cancer October 2024 210
- View full text via DOI
Merkliste

18
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04–2021) trial

von Bylicki, Olivier ; Guisier, Florian ; Scherpereel, Arnaud ; et al.

In Lung Cancer August 2024 194
- View full text via DOI
Merkliste

19
Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo)

von Vergnenegre, Alain ; Monnet, Isabelle ; Ricordel, Charles ; et al.

In Lung Cancer April 2023 178:191-197
- View full text via DOI
Merkliste

20
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

von Schwartz, Gregory G. ; Gabriel Steg, P.h. ; Bhatt, Deepak L. ; et al.

In Journal of the American College of Cardiology 3 August 2021 78(5):421-433
- View full text via DOI
Merkliste

21
Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial

von Chatzis, O. ; Blanchard-Rohner, G. ; Mondoulet, L. ; et al.

In Clinical Microbiology and Infection June 2021 27(6):878-885
- View full text via DOI
Merkliste

22
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

von Blons, H. ; Oudart, J.-B. ; Merlio, J.-P. ; et al.

In Lung Cancer January 2021 151:69-75
- View full text via DOI
Merkliste

23
Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial

von Azize, G ; Fernandez, A ; Zapata, GO ; et al.

In The Lancet 12 December 2020 396(10266):1895-1904
- View full text via DOI
Merkliste

24
Antiinflammatory therapy with canakinumab for atherosclerotic disease

von Ridker P.M. ; Everett B.M. ; Thuren T. ; et al.

New England Journal of Medicine

Schlagworte: C reactive protein; canakinumab; placebo; antiinflammatory agent; interleukin 1beta; lipid; monoclonal antibody; adult; Article; atherosclerosis; bleeding; cardiovascular mortality; cardiovascular parameters; cellulitis; clinical effectiveness; controlled study; double blind procedure; drug dose comparison; drug safety; female; follow up; gout; heart infarction; human; incidence; infection; injection site reaction; leukopenia; major clinical study; male
- View full text via BASE
Merkliste

25
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

von Schwartz, Gregory G. ; Steg, Ph. Gabriel ; Bhatt, Deepak L. ; et al.

In The Lancet Diabetes & Endocrinology August 2019 7(8):618-628
- View full text via DOI
Merkliste

12 3 4 5 6 7 8 9 10 11 weiter »

Sie haben nicht gefunden, wonach Sie gesucht haben? Diese Services können Ihnen weiterhelfen.
Hilfe & Kontakt ǀ Fernleihe | Hilfe zur Fernleihe ǀ Literaturvorschlag| Literaturvorschlag